CVS Jumping on Cost-plus Bandwagon
Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.
CVS Health is joining pharmacy benefit managers by offering simpler, cost-plus pricing, although it won't be available until 2025.
“CVS CostVantage will define the drug cost and related reimbursement with contracted pharmacy benefit managers (PBMs) and payers, using a transparent formula built on the cost of the drug, a set markup, and a fee that reflects the care and value of pharmacy services,” the company said in a news release this morning in advance of its investor’s day event.
CVS Pharmacy plans to launch CVS CostVantage with PBMs for their commercial payers in 2025, according to the news release.
The news release also announced the launch of a program called TrueCost, which the company will offer “client pricing reflecting the true net cost of prescription drugs, with visibility into administrative fees.” It will also be available in 2025.
Cigna Group’s Express Scripts announced plans to offer a “cost-plus” drug pricing model in November.
Pharmacy benefit managers (PBMs) especially the ‘big three” — CVS Caremark, Express Scripts and Optum Rx — have been under pressure to make their complicated, often obscure pricing tactics more transparent. Mark Cuban, the owner of the NBA’s Dallas Mavericks and a “Shark Tank” judge, co-founded Mark Cuban Cost Plus Drugs in early 2022 with a simple mark-up pricing strategy that Express Scripts and CVS Caremark appear to be emulating.
Several PBM reform bills have been introduced in Congress that would also require more reporting and transparency.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More
